CoChat
Sign Up
Cited by 144

The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review

Travis, Nargiz, Warner, Kenneth E, Goniewicz, Maciej L, Oh, Hayoung, Ranganathan, Radhika, Meza, Rafael, Hartmann-Boyce, Jamie, Levy, David T·2025·Nicotine and Tobacco Research
DOI 10.1093/ntr/ntae131PMC PMC11931220
Open this paper in CoChat — free account

Abstract

Introduction: Oral nicotine pouches (ONPs) are a new class of nicotine products. This scoping review summarizes evidence on ONPs and explores their potential public health impact. Aims and Methods: We conducted a structured literature search for empirical studies across three electronic databases through January 10, 2024. Outcomes included ONP product characteristics, use patterns, beliefs and perceptions, toxicity, and marketing and sales. Results: Sixty-two studies were included, 17 were industry-funded. Most studies were from the United States. While large variations across studies were observed in ONP youth prevalence estimates, nationally representative U.S. studies find current use at 1.5% and lifetime use below 2.5% through 2023. Between 35% and 42% of U.S. adolescents and young adults have heard of ONPs, and 9-21% of tobacco-naïve youth were susceptible to trying them. U.S. adult-use estimates varied widely (0.8%–3% current; 3%–16% lifetime use) and were limited to populations with a history of tobacco use. The chemical composition of ONPs suggests fewer harmful/potentially harmful compounds at lower levels than cigarettes and smokeless tobacco (SLT), except formaldehyde. Industry-funded studies find substantially less cytotoxicity compared to cigarettes and suggest that higher nicotine-strength ONPs can deliver nicotine at levels comparable to or higher than SLT or cigarettes, although with slower nicotine release than cigarettes. Evidence on the cytotoxicity of ONPs relative to SLT is mixed. Conclusions: ONPs appear to be less toxic than cigarettes and deliver comparable nicotine, presenting an alternative for combustible product users, although key data are mainly available from industry-funded studies. Data from independent research is critically needed. Industry marketing of ONPs may encourage initiation in youth and situational and dual use in adults. Implications: The review provides an initial assessment of the potential role of ONPs in harm reduction and aims to determine unintended consequences of their use (youth uptake and dual-use) and identify populations that disproportionately use the product. This information is essential for tobacco regulatory bodies in determining the net public health impact of nicotine pouches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ntr/ntae131

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 91

  1. [1]Dai H, Leventhal AM. Prevalence of e-cigarette use among adults in the United States, 2014-2018. JAMA. 2019; 322(18): 1824. 31524940 PMC6749536
  2. [2]Beard E, West R, Michie S, Brown J. Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time-series analysis between 2006 and 2017. Addiction. 2019; 115(5): 961– 974. 31621131 PMC7187187
  3. [3]Filippidis FT, Laverty AA, Gerovasili V, Vardavas CI. Two-year trends and predictors of e-cigarette use in 27 European Union member states. Tob Control. 2017; 26(1): 98– 104. 27220621 PMC5256312
  4. [4]Gravely S, Driezen P, Ouimet J, et al Prevalence of awareness, ever-use and current use of nicotine vaping products (NVPs) among adult current smokers and ex-smokers in 14 countries with differing regulations on sales and marketing of NVPs: cross-sectional findings from the ITC Project. Addiction. 2019; 114(6): 1060– 1073. 30681215 PMC6510648
  5. [5]Igarashi A, Aida J, Kusama T, et al Heated tobacco products have reached younger or more affluent people in Japan. J Epidemiol. 2021; 31(3): 187– 193. 32224597 PMC7878708
  6. [6]Stoklosa M, Cahn Z, Liber A, Nargis N, Drope J. Effect of IQOS introduction on cigarette sales: evidence of decline and replacement. Tob Control. 2020; 29(4): 381– 387. 31209129
  7. [7]Hwang JH, Ryu DH, Park SW. Heated tobacco products: cigarette complements, not substitutes. Drug Alcohol Depend. 2019; 204: 107576. 31586808
  8. [8]Kang SY, Lee S, Cho HJ. Prevalence and predictors of heated tobacco product use and its relationship with attempts to quit cigarette smoking among Korean adolescents. Tob Control. 2020; 30(2): 192– 198. 32108085
  9. [9]Jablonski JJ, Cheetham AG, Martin AM. Market survey of modern oral nicotine products: determination of select HPHCs and comparison to traditional smokeless tobacco products. SEPARATIONS. 2022; 9(3): 65.
  10. [10]Robichaud MO, Seidenberg AB, Byron MJ. Tobacco companies introduce ‘tobacco-. free’ Nicotine Pouches. Tob Control. 2020; 29(e1): e145– e146. 31753961 PMC7239723
  11. [11]Duren M, Atella L, Welding K, Kennedy RD. Nicotine pouches: a summary of regulatory approaches across 67 countries. Tob Control. 2023; 33: e32– e40. 36750358
  12. [13]Majmundar A, Okitondo C, Xue A, et al Nicotine pouch sales trends in the US by volume and nicotine concentration levels from 2019 to 2022. JAMA Netw Open. 2022; 5(11): e2242235. 36378312 PMC9667333
  13. [14]Levy DT, Warner KE, Liber AC, et al Potential implications for tobacco industry transformation of the acquisition of Swedish match by Philip Morris International. Nicotine Tob Res. 2023; 25(12): 1899– 1903. 37535864 PMC10664079
  14. [15]Emery SL, Binns S, Carter CC, Rose SW, Kostygina G. Characterising advertising strategies and expenditures for conventional and newer smokeless tobacco products. Tob Control. 2022; 32: 795– 798. 35803674 PMC9942710
  15. [16]Hrywna M, Gonsalves NJ, Delnevo CD, Wackowski OA. Nicotine pouch product awareness, interest and ever use among US adults who smoke, 2021. Tob Control. 2022; 32: 782– 785. 35217596 PMC9402802
  16. [17]Felicione NJ, Schneller LM, Goniewicz ML, et al Oral nicotine product awareness and use among people who smoke and vape in the U.S. Am J Prev Med. 2022; 63(4): 611– 618. 35667923 PMC9509436
  17. [18]Walley SC, Wilson KM, Winickoff JP, Groner J. A public health crisis: electronic cigarettes, vape, and JUUL. Pediatrics. 2019; 143(6): e20182741. 31122947
  18. [19]Collins L, Glasser AM, Abudayyeh H, Pearson JL, Villanti AC. E-cigarette marketing and communication: how E-Cigarette Companies Market E-Cigarettes and the public engages with E-cigarette Information. Nicotine & Tobacco Research. 2019; 21(1): 14– 24. 29315420 PMC6610165
  19. [20]Tackett AP, Barrington-Trimis JL, Leventhal AM. ‘Flavour ban approved’: new marketing strategies from tobacco-free nicotine pouch maker Zyn. Tob Control. 2022; 32: e134– e135. 35459750 PMC9587134
  20. [21]Talbot EM, Giovenco DP, Grana R, Hrywna M, Ganz O. Cross-promotion of nicotine pouches by leading cigarette brands. Tob Control. 2021; 32: 528– 529. 34670870 PMC9018875
  21. [22]Sun T, Tattan-Birch H. Sports, gigs, and tiktoks: multi-channel advertising of oral nicotine pouches. Qeios 2024. PMC12824941 39191473
  22. [23]Patwardhan S, Fagerstrom K. The new nicotine pouch category- a tobacco harm reduction tool? Nicotine Tob Res. 2021; 24(4): 623– 625. PMC8887571 34606613
  23. [24]Salokannel M, Ollila E. Snus and snus-like nicotine products moving across Nordic borders: Can laws protect young people? Nordisk Alkohol Nark. 2021; 38(6): 540– 554. 35309849 PMC8900178
  24. [25]Linnansaari A, Ollila H, Pisinger C, et al Towards Tobacco-Free Generation: implementation of preventive tobacco policies in the Nordic countries. Scand J Public Health. 2022; 51(8): 1108– 1121. 35799463 PMC10642214
  25. [26]Lund KE, Vedoy TF. A conceptual framework for assessing the public health effects from snus and novel non-combustible nicotine products. Nordisk Alkohol Nark. 2021; 38(6): 586– 604. 35309855 PMC8900171
  26. [28]Schneller LM, Felicione NJ, Hammond D, Goniewicz ML, O’Connor RJ. Tobacco-free oral nicotine product use among youth in the U.S., 2019-2021. AJPM Focus. 2023; 2(1): 100061. 37789938 PMC10546555
  27. [29]Kramer RD, Park-Lee E, Marynak KL, et al Nicotine pouch awareness and use among youth, National Youth Tobacco Survey, 2021. Nicotine Tob Res. 2023; 25(9): 1610– 1613. 37279928 PMC10961705
  28. [30]Gentzke AS, Wang TW, Cornelius M, et al Tobacco product use and associated factors among middle and high school students - national youth tobacco survey, United States, 2021. MMWR Surveill Summ. 2022; 71(5): 1– 29. PMC8923300 35271557
  29. [31]Park-Lee E, Ren C, Cooper M, et al Tobacco product use among middle and high school students - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(45): 1429– 1435. 36355596 PMC9707354
  30. [32]Birdsey J, Cornelius M, Jamal A, et al Tobacco product use among U.S. middle and high school students - National Youth Tobacco Survey, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(44): 1173– 1182. 37917558 PMC10629751
  31. [33]East KA, Reid JL, Rynard VL, Hammond D. Trends and patterns of tobacco and nicotine product use among youth in Canada, England, and the United States from 2017 to 2019. J Adolesc Health. 2021; 69(3): 447– 456. 33839006 PMC8403620
  32. [34]Harlow AF, Vogel EA, Tackett AP, et al Adolescent use of flavored non-tobacco oral nicotine products. Pediatrics. 2022; 150(3): e2022056586. 35934731 PMC9994602
  33. [35]Patel M, Kierstead EC, Kreslake J, Schillo BA. Patterns of oral nicotine pouch use among U.S. adolescents and young adults. Prev Med Rep. 2023; 34: 102239. 37228836 PMC10203764
  34. [36]Gaiha SM, Lin C, Lempert LK, Halpern-Felsher B. Use, marketing, and appeal of oral nicotine products among adolescents, young adults, and adults. Addict Behav. 2023; 140: 107632. 36731224
  35. [37]Couch ET, Halpern-Felsher B, Werts M, Chaffee BW. Use of emerging and conventional oral tobacco among Adolescent and Young Adult E-Cigarette Users. Subst Use Misuse. 2023; 58(2): 283– 288. 36645845 PMC10084808
  36. [38]Sparrock LS, Phan L, Chen-Sankey J, et al Nicotine pouch: awareness, beliefs, use, and susceptibility among current tobacco users in the United States, 2021. Int J Environ Res Public Health. 2023; 20(3): 2050. 36767414 PMC9915420
  37. [39]Li L, Borland R, Cummings KM, et al Patterns of non-cigarette tobacco and nicotine use among current cigarette smokers and recent quitters: findings from the 2020 ITC four country smoking and vaping survey. Nicotine Tob Res. 2021; 23(9): 1611– 1616. 33693833 PMC8562420
  38. [40]Tosakoon S, Romm KF, Berg CJ. Nicotine pouch awareness, use and perceptions among young adults from six metropolitan statistical areas in the United States. Tob Prev Cessat. 2023; 9: 19. 37293565 PMC10246475
  39. [41]Morean ME, Bold KW, Davis DR, et al Awareness, susceptibility, and use of oral nicotine pouches and comparative risk perceptions with smokeless tobacco among young adults in the United States. PLoS One. 2023; 18(1): e0281235. 36716297 PMC9886243
  40. [42]Morean ME, Bold KW, Davis DR, et al “Tobacco-free” nicotine pouches: risk perceptions, awareness, susceptibility, and use among young adults in the United States. Nicotine Tob Res. 2022; 25(1): 143– 150. PMC9717372 36000776
  41. [43]Havermans A, Pennings JLA, Hegger I, et al Awareness, use and perceptions of cigarillos, heated tobacco products and nicotine pouches: a survey among Dutch adolescents and adults. Drug Alcohol Depend. 2021; 229(Pt B): 109136. 34763136
  42. [44]Tattan-Birch H, Jackson SE, Dockrell M, Brown J. Tobacco-free nicotine pouch use in Great Britain: a representative population survey 2020-2021. Nicotine Tob Res. 2022; 24(9): 1509– 1512. 35417551 PMC9356773
  43. [45]Brose LS, McDermott MS, McNeill A. Heated tobacco products and nicotine pouches: a survey of people with experience of smoking and/or vaping in the UK. Int J Environ Res Public Health. 2021; 18(16): 8852. 34444601 PMC8391640
  44. [46]Plurphanswat N, Hughes JR, Fagerstrom K, Rodu B. Initial information on a novel nicotine product. Am J Addict. 2020; 29(4): 279– 286. 32176374
  45. [47]Dowd AN, Thrul J, Czaplicki L, et al A cross-sectional survey on oral nicotine pouches: characterizing use-motives, topography, dependence levels, and adverse events. Nicotine Tob Res. 2024; 26(2): 245– 249. 37712111 PMC10803111
  46. [48]Vogel EA, Barrington-Trimis JL, Kechter A, et al Differences in young adults’ perceptions of and willingness to use nicotine pouches by tobacco use Status. Int J Environ Res Public Health. 2022; 19(5): 2685. 35270385 PMC8910652
  47. [49]Vogel EA, Barrington-Trimis JL, Harlow AF, et al Prevalence of and disparities in adolescents’ susceptibility to novel oral nicotine products marketed as “tobacco-free.”. Prev Med. 2023; 166: 107387. 36503016 PMC9845133
  48. [50]Tackett AP, Wong M, Cho J, et al Willingness to use commercial nicotine gums, lozenges, and gummies among nontobacco using adolescents in Southern California. J Adolesc Health. 2023; 72(2): 277– 286. 36470691 PMC9994582
  49. [51]Keller-Hamilton B, Curran H, Stevens EM, et al Effects of “Tobacco Free” language in warning labels on perceptions of electronic cigarettes and nicotine pouches among young adult men: a randomized trial. Subst Use Misuse. 2023; 58(10): 1302– 1306. 37227265 PMC10401609
  50. [52]Morean ME, Gueorguieva R, O’Malley S, Krishnan-Sarin S. Including the term ‘tobacco-free nicotine’ in the nicotine addiction warning label mandated by the US Food and Drug Administration alters risk perceptions and use intentions. Tob Control. 2023: tc– 2023. PMC11055938 37898544
  51. [53]Vogel EA, Tackett AP, Unger JB, et al Effects of flavour and modified risk claims on nicotine pouch perceptions and use intentions among young adults who use inhalable nicotine and tobacco products: a randomised controlled trial. Tob Control. 2023: tc– 2023. PMC11199376 38148143
  52. [54]Long L, Alalwan MA, Keller-Hamilton B, et al Perceptions of oral nicotine pouches & their marketing among Ohio Appalachia smokers and smokeless tobacco users. PLoS One. 2023; 18(10): e0293597. 37903103 PMC10615305
  53. [55]Mays D, Long L, Alalwan MA, et al The effects of oral nicotine pouch packaging features on adult tobacco users’ and non-users’ product perceptions. Int J Environ Res Public Health. 2023; 20(4): 3383. 36834078 PMC9965054
  54. [56]Keller-Hamilton B, Alalwan MA, Curran H, et al Evaluating the effects of nicotine concentration on the appeal and nicotine delivery of oral nicotine pouches among rural and Appalachian adults who smoke cigarettes: a randomized cross-over study. Addiction. 2023; 119(3): 464– 475. 37964431 PMC10872395
  55. [58]Rensch J, Liu J, Wang J, et al Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on! nicotine pouches compared to combustible cigarettes. Psychopharmacology (Berl). 2021; 238(11): 3325– 3334. 34432106
  56. [60]Chapman F, McDermott S, Rudd K, et al A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes. Psychopharmacology (Berl). 2022; 239(9): 2931– 2943. 35732751 PMC9217727
  57. [61]Azzopardi D, Ebajemito J, McEwan M, et al A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. Sci Rep. 2022; 12(1): 6949. 35484309 PMC9050656
  58. [62]Stanfill S, Tran H, Tyx R, et al Characterization of total and unprotonated (free) nicotine content of nicotine pouch products. Nicotine Tob Res. 2021; 23(9): 1590– 1596. 34233354
  59. [63]Mallock N, Schulz T, Malke S, et al Levels of nicotine and tobacco-specific nitrosamines in oral nicotine pouches. Tob Control. 2024; 33: 193– 199. 38378209
  60. [65]Mallock-Ohnesorg N, Rinaldi S, Malke S, et al Oral nicotine pouches with an aftertaste? Part 1: screening and initial toxicological assessment of flavorings and other ingredients. Arch Toxicol. 2023; 97(9): 2357– 2369. 37389646 PMC10404176
  61. [66]Back S, Masser AE, Rutqvist LE, Lindholm J. Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs). BMC Chem. 2023; 17(1): 9. 36869349 PMC9985244
  62. [67]Azzopardi D, Liu C, Murphy J. Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem Toxicol. 2022; 45(5): 2246– 2254. 34034614
  63. [68]Bishop E, East N, Bozhilova S, et al An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches. Food Chem Toxicol. 2020; 145: 111713. 32998027
  64. [69]East N, Bishop E, Breheny D, Gaca M, Thorne D. A screening approach for the evaluation of tobacco-free ‘modern oral’ nicotine products using Real Time Cell Analysis. Toxicol Rep. 2021; 8: 481– 488. 33718000 PMC7933807
  65. [70]Yu F, Rudd K, Pour SJ, et al Preclinical assessment of tobacco-free nicotine pouches demonstrates reduced in vitro toxicity compared with tobacco snus and combustible cigarette smoke. Applied In Vitro Toxicology. 2022; 8(1): 24– 35.
  66. [71]Alizadehgharib S, Lehrkinder A, Alshabeeb A, Ostberg AK, Lingstrom P. The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus). Eur J Oral Sci. 2022; 130(4): e12885. 35853092 PMC9540014
  67. [72]Shaikh S, Tung WC, Lucas J, et al Flavor classification/categorization and differential toxicity of oral nicotine pouches (ONPs) in lung epithelial cells. bioRxiv. 2022. PMC9696007 36355951
  68. [73]Shaikh SB, Tung WC, Pang C, et al Flavor classification/categorization and differential toxicity of Oral Nicotine Pouches (ONPs) in oral gingival epithelial cells and bronchial epithelial cells. Toxics. 2022; 10(11): 660. 36355951 PMC9696007
  69. [74]Miller-Holt J, Baskerville-Abraham I, Sakimura M, et al In vitro evaluation of mutagenic, cytotoxic, genotoxic and oral irritation potential of nicotine pouch products. Toxicol Rep. 2022; 9: 1316– 1324. 36518473 PMC9742906
  70. [75]Rinaldi S, Pieper E, Schulz T, et al Oral nicotine pouches with an aftertaste? Part 2: in vitro toxicity in human gingival fibroblasts. Arch Toxicol. 2023; 97(9): 2343– 2356. 37482550 PMC10404181
  71. [76]Dalrymple A, Bean EJ, Badrock TC, et al Enamel staining with e-cigarettes, tobacco heating products and modern oral nicotine products compared with cigarettes and snus: an in vitro study. Am J Dent. 2021; 34(1): 3– 9. 33544982
  72. [77]Azzopardi D, Haswell LE, Frosina J, et al Assessment of biomarkers of exposure and potential harm, and physiological and subjective health measures in exclusive users of nicotine pouches and current, former and never smokers. Biomarkers. 2023; 28(1): 118– 129. 36484137
  73. [78]Rensch J, Edmiston J, Wang J, Jin X, Sarkar M. A randomized, controlled study to assess changes in biomarkers of exposures among adults who smoke that switch to oral nicotine pouch products relative to continuing smoking or stopping all tobacco use. J Clin Pharmacol. 2023; 63(10): 1108– 1118. 37322571
  74. [79]Delnevo CD, Hrywna M, Miller Lo EJ, Wackowski OA. Examining market trends in smokeless tobacco sales in the United States: 2011-2019. Nicotine Tob Res. 2021; 23(8): 1420– 1424. 33241271 PMC8360632
  75. [80]Marynak KL, Wang X, Borowiecki M, et al Nicotine Pouch Unit Sales in the US, 2016-2020. JAMA. 2021; 326(6): 566– 568. 34374729 PMC8356066
  76. [81]Ling PM, Hrywna M, Talbot EM, Lewis MJ. Tobacco-derived nicotine pouch brands and marketing messages on internet and traditional media: content analysis. JMIR Form Res. 2023; 7: e39146. 36790840 PMC9978966
  77. [82]Czaplicki L, Patel M, Rahman B, et al Oral nicotine marketing claims in direct-mail advertising. Tob Control. 2022; 31(5): 663– 666. 33958422 PMC9411885
  78. [83]Rose SW, Annabathula A, Westneat S, et al Neighborhood distribution of availability of newer tobacco products: a four-site study, 2021. medRxiv. 2022; 30: 102028. PMC9619027 36325253
  79. [84]Phillip Morris International. Philip Morris International Reports 2023 Third-Quarter and Nine-Month Year-to-Date Results. https://www.pmi.com/media-center/press-releases/press-details?newsId=26881. 2023. Accessed February 11, 2023.
  80. [85]Altria. Altria Reports 2023 Second-quarter and First-half Results; Reaffirms 2023 Full-Year Earnings Guidance. https://www.altria.com/-/media/Project/Altria/Altria/Investors/events-and-presentations/2023/2023-Q2/Press-Release.pdf. Accessed February 11, 2023.
  81. [86]Hrywna M, Ozga JE, Stanton CA, et al Prioritizing common terminology and measures to advance research on oral nicotine product use. Nicotine Tob Res. 2023; 26(5): 645– 648. PMC11033571 37846819
  82. [87]National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US); 2014. https://www.ncbi.nlm.nih.gov/books/NBK179276/ 24455788
  83. [88]IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monogr Eval Carcinog Risks Hum. 2007; 89: 1– 592. 18335640 PMC4781254
  84. [90]Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005; 120(2): 200– 208. 15842123 PMC1497700
  85. [92]Inoue-Choi M, Shiels MS, McNeel TS, et al Contemporary associations of exclusive cigarette, cigar, pipe, and smokeless tobacco use with overall and cause-specific mortality in the United States. JNCI Cancer Spectr. 2019; 3(3): pkz036. 31321380 PMC6620791
  86. [93]Hendlin YH, Small S, Ling PM. ‘No-Barriers’ tobacco product? Selling smokeless tobacco to women, people of colour and the LGBTQ+ community in the USA. Tob Control. 2021; 32: 330– 337. 34599083 PMC10171187
  87. [97]Morean ME, Bold KW, Davis DR, et al Does it come from tobacco? Young adults’ interpretations of the term “tobacco-free nicotine” in a cross-sectional national survey sample. PLoS One. 2022; 17(5): e0268464. 35559988 PMC9106148
  88. [98]Kostygina G, England L, Ling P. New product marketing blurs the line between nicotine replacement therapy and smokeless tobacco products. Am J Public Health. 2016; 106(7): 1219– 1222. 27077338 PMC4984756
  89. [99]Ling PM, Kim M, Egbe CO, et al Moving targets: how the rapidly changing tobacco and nicotine landscape creates advertising and promotion policy challenges. Tob Control. 2022; 31(2): 222– 228. 35241592 PMC9233523
  90. [101]Jabba SV, Erythropel HC, Woodrow JG, et al Synthetic cooling agent in oral nicotine pouch products marketed as ‘Flavour-Ban Approved’. Tob Control. 2023: tc– 2023. PMC10753027 37380351
  91. [103]Lee PN, Fry JS, Ljung T. Estimating the public health impact had tobacco-free nicotine pouches been introduced into the US in 2000. BMC Public Health. 2022; 22(1): 1025. 35597944 PMC9123784

Cited by

Sorted by citations

Authors
Travis, N., Warner, K. E., Goniewicz, M. L., Oh, H., Ranganathan, R., Meza, R., Hartmann-Boyce, J., & Levy, D. T.
Venue
Nicotine and Tobacco Research
Publisher
Oxford University Press (OUP)
Published
2024-06-17
Volume
27
Issue
4
Pages
598-610
ISSN
1469-994X
DOI
10.1093/ntr/ntae131
PMC
PMC11931220
Cited by
144
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Cancer Institute
  • Food and Drug Administration (U54CA229974)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review